Literature DB >> 2787783

In vivo biology of recombinant interleukin-2 infusion in sheep: cardiopulmonary manifestations of an intravascular immune-inflammatory response.

G J Jesmok1, R A Gunther.   

Abstract

We have described the physiologic changes that occur in the conscious sheep during five days of dosing with rIL-2. Major effects noted were a decrease in systemic vascular resistance (vasodilation) accompanied by an increase in cardiac output (blood flow) and heart rate and a mild increase in pulmonary vascular resistance (vasoconstriction). Body temperature increased and may have contributed to the peripheral vasodilation. Lung microvascular fluid and protein flux increased following rIL-2 administration, as evidenced by an increase in lung lymph flow and protein clearance, and circulating levels of leukocytes decreased. These phenomena were temporally related. Since the composite biologic response that occurred following rIL-2 administration was characterized by changes in vascular caliber and blood flow, increased vascular permeability, and margination of leukocytes, we propose that the response be viewed as an intravascular inflammatory reaction.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787783     DOI: 10.1007/bf00914394

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  35 in total

1.  Effects of graded increases in pulmonary vascular pressures on lung fluid balance in unanesthetized sheep.

Authors:  R E Parker; R J Roselli; T R Harris; K L Brigham
Journal:  Circ Res       Date:  1981-11       Impact factor: 17.367

2.  Adoptive immunotherapy for stage IV renal cell carcinoma: a novel protocol utilizing periodate and interleukin-2-activated autologous leukocytes and continuous infusions of low-dose interleukin-2.

Authors:  J Wang; A Walle; B Gordon; A Novogrodsky; M Suthanthiran; A L Rubin; H Morrison; R T Silver; K H Stenzel
Journal:  Am J Med       Date:  1987-12       Impact factor: 4.965

3.  Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes.

Authors:  M Malkovský; B Loveland; M North; G L Asherson; L Gao; P Ward; W Fiers
Journal:  Nature       Date:  1987 Jan 15-21       Impact factor: 49.962

4.  Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer.

Authors:  M T Lotze; S A Rosenberg
Journal:  Immunobiology       Date:  1986-09       Impact factor: 3.144

5.  Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues.

Authors:  A Wang; S D Lu; D F Mark
Journal:  Science       Date:  1984-06-29       Impact factor: 47.728

6.  Natural killer (NK) cells as a responder to interleukin 2 (IL 2). II. IL 2-induced interferon gamma production.

Authors:  K Handa; R Suzuki; H Matsui; Y Shimizu; K Kumagai
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

7.  Uptake of bloodborne bacteria by pulmonary intravascular macrophages and consequent inflammatory responses in sheep.

Authors:  A E Warner; R M Molina; J D Brain
Journal:  Am Rev Respir Dis       Date:  1987-09

8.  Biological activity of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  S A Rosenberg; E A Grimm; M McGrogan; M Doyle; E Kawasaki; K Koths; D F Mark
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

9.  Structure and expression of a cloned cDNA for human interleukin-2.

Authors:  T Taniguchi; H Matsui; T Fujita; C Takaoka; N Kashima; R Yoshimoto; J Hamuro
Journal:  Nature       Date:  1983 Mar 24-30       Impact factor: 49.962

10.  Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.

Authors:  E A Grimm; K M Ramsey; A Mazumder; D J Wilson; J Y Djeu; S A Rosenberg
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.